CASSS is an agile, non-profit scientific organization whose strength is in bringing together professionals from industry, academia and regulatory agencies to solve scientific and technical problems in order to advance the development of biopharmaceuticals. CASSS enables regulatory capacity building, knowledge-sharing and global access by leveraging strategic partnerships, scientific expertise and a diversity of views in all of our activities.
The CASSS Cell and Gene Therapy Products symposium enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products. The CGTP 2021 Symposium will explore how to continue to adapt concepts applied to other biologics and how to establish novel approaches where they are needed.
Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.